Aerobic exercise slows Parkinson progression
- Trial ID
- NCT05854524
- Official Title
- Exploring the Biological Basis for Exercise Neuroprotection in Parkinson's Disease
- Goal
- Aerobic exercise slows Parkinson progression
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University of Nevada, Las Vegas
- Study Type
- INTERVENTIONAL
- Enrollment
- 90 participants
- Conditions
- Parkinson Disease
- Interventions
- Aerobic exercise
Plain-Language Summary
Goal: to find out how moderate aerobic exercise might protect dopamine-producing brain cells in Parkinson's by triggering biological changes that support brain health. Approach: participants do 30 minutes of continuous moderate aerobic exercise with 2-3 short breaks while researchers measure blood markers and other signals, looking for increased blood flow and growth factors like BDNF, improved mitochondrial function, and reduced inflammation. The study compares people with Parkinson's to healthy adults to see which responses are disease-specific. Eligibility: adults 30 to 85, people with Parkinson's must have a neurologist diagnosis and be able to do the 30-minute exercise; anyone with major exercise risks, uncontrolled cardiovascular or respiratory issues, or dementia (MoCA 21 or below) is excluded, and controls must be generally healthy and able to exercise.
Locations
- Gait and Balance Laboratory, 217 Bigelow Health Sciences Building, UNLV, Las Vegas, Nevada, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Aerobic exercise. Goal: to find out how moderate aerobic exercise might protect dopamine-producing brain cells in Parkinson's by triggering biological changes that support brain health. Approach: participants do 30 minutes of continuous moderate aerobic exercise with 2-3 short breaks while researchers measure blood markers and other signals, looking for increased blood flow and growth factors like BDNF, improved mitochondrial function, and reduced inflammation. The study compares people with Parkinson's to healthy adults to see which responses are disease-specific. Eligibility: adults 30 to 85, people with Parkinson's must have a neurologist diagnosis and be able to do the 30-minute exercise; anyone with major exercise risks, uncontrolled cardiovascular or respiratory issues, or dementia (MoCA 21 or below) is excluded, and controls must be generally healthy and able to exercise.
- Who can participate?
- Participants must be between 30 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 9 months.